Related Experiment Video

Updated: Jan 28, 2026

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
06:47

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure

Published on: November 29, 2018

10.1K

Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure

Simei Sun1,2,3,4, Hae Jin Kee5,6, Yuhee Ryu2,3

  • 1Zhoushan Hospital, Zhejiang University School of Medicine, No 739, Dingshen Road Lincheng New District, Zhoushan Zhejiang, 316021, China.

Scientific Reports
|March 1, 2019
PubMed

Insights

Gentisic acid prevents heart failure progression by reducing cardiac hypertrophy, fibrosis, and dysfunction in mice. This natural compound shows promise for managing heart disease.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Biochemistry

Background:

  • Cardiac hypertrophy and fibrosis are key pathological features preceding heart failure.
  • The renin-angiotensin-aldosterone system plays a critical role in cardiovascular remodeling and disease progression.
  • Gentisic acid has previously shown potential in attenuating cardiac hypertrophy and fibrosis.

Purpose of the Study:

  • To investigate the efficacy of gentisic acid in preventing the development of heart failure.
  • To evaluate the effects of gentisic acid on cardiac dysfunction, hypertrophy, fibrosis, and related molecular pathways.
  • To assess the impact of gentisic acid on pulmonary vascular remodeling in a heart failure model.

Main Methods:

  • Heart failure was induced in mice using chronic transverse aortic constriction (TAC).
  • Mice were treated with vehicle, gentisic acid (10 and 100 mg/kg/day), or bisoprolol (0.5 mg/kg/day) for 3 weeks post-TAC.
  • Cardiac function, hypertrophy, fibrosis, gene expression (fibrosis markers, RAAS), and lung pathology were assessed using various techniques including western blotting, qPCR, and histology.

Main Results:

  • Gentisic acid administration inhibited cardiac dysfunction in a dose-dependent manner.
  • The compound significantly reduced cardiac hypertrophy and fibrosis, as evidenced by molecular and histological analyses.
  • Gentisic acid dose-dependently suppressed fibrosis marker gene expression, inhibited the renin-angiotensin-aldosterone system, and ameliorated pulmonary vascular remodeling.

Conclusions:

  • Gentisic acid effectively prevents cardiac hypertrophy, fibrosis, and cardiac dysfunction in a mouse model of TAC-induced heart failure.
  • The findings suggest gentisic acid's potential to inhibit the renin-angiotensin-aldosterone system and reduce pulmonary pathology associated with heart failure.
  • Supplementation with gentisic acid may offer a therapeutic advantage in preventing the progression from cardiac hypertrophy to overt heart failure.

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

17.6K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272